




Likang Life Sciences
Create more accurate and
powerful immune weapons for fighting cancer
Scientific Platform
In personalized tumor immunotherapy, appropriate drug forms are selected for clinical treatment according to different indications based on the identification and screening of tumor-specific neoantigens. We developed Likang Neoantigen Epitope Analysis (LNEA) platform and dendritic cell (DC) loaded with tumor-specific neoantigens, neoantigen specific T cell (Neo-T), transgenic T cell (TCR-T), and etc. which may enable us to predict the presence of unique neoantigens in tumor cells of patients, and based on multiple product lines, gradually promote individualized tumor immunotherapy to clinical application.


A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma
To view more
